Mind Medicine (MNMD): A psychedelic stock for long-term holders?

Be the First to Comment Read

Mind Medicine (MNMD): A psychedelic stock for long-term holders?

Mind Medicine (MNMD) stock
Image source: © Allexxe | Megapixl.com
Highlights:
  • Mind Medicine develops therapies out of psychedelic compounds like psilocybin to treat mental health and addiction disorders.
  • Since the past month, MNMD stock declined 40 per cent, and it is 82 per cent down compared to the 52-week high.
  • At the end of the trading session on January 18, MNMD stock's price was US$ 1.03 per share. However, this price could grow in future.

Stocks of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) declined eight per cent on Tuesday, January 18. However, the latest update from the company could have left investors hooked onto the New York-based company.

Mind Medicine develops therapies out of psychedelic compounds like psilocybin to treat mental health and addiction disorders. On Tuesday, the company announced that it enrolled first subjects for a study named Session Monitoring System (SMS-01).

Under the study, Mind Medicine will evaluate a passive collection of sensory data during a therapeutic session. According to the company statement, SMS-01 will utilize MindMed's Session Monitoring System (MSMS).

MSMS is MindMed's technological platform, and it provides the foundation for the development of products for use by clinicians during treatment sessions of patients.

Mind Medicine (MNMD) stock for long-term holders?


At the end of the trading session on January 18, MNMD stock's price was US$ 1.03 per share. However, this price could grow in future.

According to many studies, Psychedelic therapies are effective in treating mental health disorders.

Over the years, people have started to talk about depression, and the focus on treating mental health issues has increased. As a result, companies exploring psychedelic-based therapies could expand in future.

MNMD stock                                                                                         ©2022 Kalkine Media® 

A 2021 study in JAMA Psychiatry, a journal published by the American Medical Association, stated that random clinical trials discovered that psilocybin-assisted therapies effectively produced sustained antidepressant effects in patients with depressive disorder.

Recently, MindMed consulted the Center for Devices, Radiological Health (CDRH) and Center for Drug Evaluation and Research (CDER) for its planned development strategy and received positive feedback.

Notably, both the centers are under the US Food and Drug Administration, and the feedback has given a roadmap to MindMed for the adoption of MSMS.

Bottom line


Since the past month, MNMD stock declined 40 per cent, and it is 82 per cent down in comparison to the 52-week high of US$ 5.77 per share on April 27, 2021.

Mind Medicine stock could be an option for long-term investors as psychedelic therapies could become mainstream in future and increase the revenue of companies exploring this sector.

As of September 30, 2021, MindMed's total assets were US$ 178.6 million, which included cash worth US$ 145.9 million.

Disclaimer

Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK